Abstract
HF readmissions is an important quality measure for US hospitals. In Paradigm-HF, systolic HF pts demonstrated reduced HF admissions and improved mortality when treated with sacubitril/valsartan (S/V). We reviewed charts of pts started on S/V in the Mercy Health (MH) system since July, 2015. Data
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
